19 April 2019
Pictured: (L-R) Shelly Jackson (Austrade) James Choi (Australian Ambassador to Korea) and Rodney Commerford Trade Commissioner & Counsellor (Austrade) at BioKorea in Seoul.
This week the MTPConnect team has had a real focus on the important MTP market of Korea, where our CEO, Dr Dan Grant, is attending BioKorea2019.
Dan represented MTPConnect supporting Austrade’s delegation, where he had a meeting with Australian Ambassador to Korea James Choi, Austrade’s Shelly Jackson & Trade Commissioner Rodney Commerford to discuss strengthening links in this important biotech international market.
At the conference, Dan is presenting during the half-day “Strategic Partnership Conference of Korean – Australian Health Industry” session. He is promoting the strengths of Australia’s clinical trials capabilities, highlighting the factors that make Australia a country of choice for companies looking to conduct clinical trials. As part of that, he will also chair a panel session focused on the opportunities for Korean companies to leverage Australia’s clinical trials expertise.
He is participating in the panel will be representatives from some of Australia’s leading clinical trial’s organisations, including Novotech, Southern Star Resaerch, George Clinical, Neuroscience Trials Australia, Paratus Clinical, Neucleus network, 360 Biolabs, Luina Bio and BIPFocus along with Korean representatives from ToolGen and PharmAbcine.
On Friday Dan will present at the conference’s “Medical Innovation by Regenerative Medicine - Australia Korea Regenerative Medicine” session exploring Australia’s roadmap to promote Regenerative medicine that was highlighted in MTPConnect’s Regenerative Medicine report.